NRSN

Neurosense Therapeutics Ltd. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website neurosense-tx.com
Employees(FY) 14
ISIN IL0011809592

Performance

-7.09%

1W

-31.4%

1M

-9.23%

3M

+122.64%

6M

+50.32%

YTD

-34.08%

1Y

Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. Its lead product is PrimeC, an extended-release oral formulation of a fixed dose combination of ciprofloxacin and celecoxib for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

Advanced Technical Analysis

Technical Analysis of NRSN 2024-05-10

Overview:

In analyzing the technical indicators for NRSN over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key aspects, we aim to offer valuable insights and predictions for the upcoming days.

Trend Analysis:

...

See more ...

Recent News & Updates

2024-05-06 20:45
NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients(Prnewswire)
2024-05-01 21:19
NeuroSense Announces First Quarter 2024 Business Update(Prnewswire)
2024-04-21 20:30
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease(Prnewswire)
2024-04-17 20:30
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting(Prnewswire)
2024-04-11 20:30
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024(Prnewswire)
2024-04-10 07:16
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement(Prnewswire)
2024-04-08 20:30
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics(Prnewswire)
2024-04-05 08:52
NRSN Stock Earnings: NeuroSense Therapeutics Beats EPS for Q4 2023(Investorplace)
2024-04-04 21:29
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update(Prnewswire)
2024-02-20 19:30
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial(Prnewswire)
2024-02-06 20:27
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule(Prnewswire)
2024-01-29 19:30
NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024(Accesswire)
2024-01-08 19:45
NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts(Prnewswire)
2023-12-27 04:00
NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement(Prnewswire)
2023-12-13 20:24
NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial(Prnewswire)
2023-12-04 19:00
NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints(Prnewswire)
2023-12-04 03:01
NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023(Prnewswire)
2023-11-27 19:45
NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update(Prnewswire)
2023-11-12 20:20
NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness(Prnewswire)
2023-11-08 20:00
NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences(Prnewswire)
2023-11-05 19:30
NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023(Prnewswire)
2023-10-31 21:00
NeuroSense Therapeutics to Participate in BIO-Europe Fall(Prnewswire)
2023-10-18 22:30
Renowned ALS Researcher Confirms The Efficacy Of NeuroSense Therapeutics Lead Drug Candidate, PrimeC(Accesswire)
2023-10-16 20:30
NeuroSense CEO Provides Q3 2023 Update(Prnewswire)
2023-10-03 21:10
NeuroSense's PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC Model(Prnewswire)
2023-10-03 19:00
Presenting on the Emerging Growth Conference 63 Day 2 on October 5 Register Now(Globenewswire)
2023-10-02 19:00
Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now(Globenewswire)
2023-10-01 20:46
NeuroSense Ends its At-The-Market Equity Offering Program: Company is Fully Funded Beyond Clinical Phase 2b ALS Results(Prnewswire)
2023-09-19 21:05
European Medicines Agency Grants NeuroSense SME Status(Yahoo Finance)
2023-09-18 21:00
NeuroSense Granted Patents in Europe, Japan, and Israel for its ALS Drug PrimeC(Yahoo Finance)

Page 1 of 4

previousnext